Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01633489 · ClinicalTrials.gov registry record

Lysosomal Acid Lipase (LAL) Deficiency Registry

A clinical trial of Wolman Disease and Lysosomal Acid Lipase Deficiency, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
300
Enrollment target
20
Study locations

NCT01633489 is a study of Wolman Disease and Lysosomal Acid Lipase Deficiency that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 300 participants, above the 110-participant average among 4 other Wolman Disease trials with a reported enrollment target (173% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01633489, a study of Wolman Disease and Lysosomal Acid Lipase Deficiency, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
300 participants
Enrollment target
20
Study locations

Study Summary

This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.

Conditions Studied

Wolman Disease Lysosomal Acid Lipase Deficiency Cholesterol Ester Storage Disease Acid Cholesteryl Ester Hydrolase Deficiency, Type 2 Acid Lipase Deficiency LIPA Deficiency LAL-Deficiency

Study Locations (20)

Pennsylvania

  • Clinical Trial Site - Philadelphia
  • Clinical Trial Site - Philadelphia
  • Clinical Trial Site - Philadelphia

Texas

  • Clinical Trial Site - Houston
  • Clinical Trial Site - Houston
  • Clinical Trial Site - Snyder

Florida

  • Clinical Trial Site - Miramar
  • Clinical Trial Site - Orlando

New York

  • Clinical Trial Site - New York
  • Clinical Trial Site - The Bronx

Arizona

  • Clinical Trial Site - Phoenix

California

  • Clinical Trial Site - Stanford

Georgia

  • Clinical Trial Site - Atlanta

Illinois

  • Clinical Trial Site - Chicago

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2013-05-30
Est. Completion 2029-08-30

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01633489

The ClinicalTrials.gov registry entry for NCT01633489 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 4 other Wolman Disease trials with a reported enrollment target (173% higher). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Wolman Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01633489 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Pennsylvania, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT01633489 about?

NCT01633489 is a clinical study titled "Lysosomal Acid Lipase (LAL) Deficiency Registry". This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary...

What is the current status of trial NCT01633489?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2013-05-30. Estimated completion is 2029-08-30.

What conditions does trial NCT01633489 study?

This clinical trial studies the following conditions: Wolman Disease, Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency.

Who is sponsoring clinical trial NCT01633489?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01633489 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Wolman Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Wolman Disease

All registered trials for this condition

Lysosomal Acid Lipase Deficiency

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.